Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-ClaPd in Multiple Myeloma Patients Previously Exposed to Daratumumab
NCT04302324Phase 2Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Oct 2021
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, clarithromycin, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Weill Cornell Medicine. Primary endpoint: Very Good Partial Response Rate or Better up to 224 days. Started Oct 2021; status: active, not recruiting.
02
Drugs
daratumumabclarithromycinpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04302324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04302324.